FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952754917> ?p ?o ?g. }

• W2952754917 endingPage "420" @default.
• W2952754917 startingPage "419" @default.
• W2952754917 abstract "Background: Acute lymphoblastic leukemia (ALL) is formed by accumulation of lymphoblasts in bone marrow and peripheral blood. The most common subtype of ALL is philadelphia positive ALL (Ph+ ALL) which is characterized by having BCR/ABL protein. For the treatment of Ph+ALL tyrosine kinase inhibitors (TKI) such as imatinib are used. However, 60–75% of the patients can still develop resistance against the TKIs and die within 5 years. Bioactive sphingolipids are a group of lipid family having ceramide as the central molecule, that play roles in many cellular mechanisms including proliferation, apoptosis, inflammation, metastasis. Ceramide is known to induce apoptosis which makes this sphingolipid a useful tool in cancer treatment. Sphingolipids can be generated through different pathways including de novo synthesis, recycling and salvage pathways. Previous studies showed that bioactive sphingolipids and genes in the pathway have been involved in response to TKI treatment in Ph+ALL. Aims: Here, we studied the roles of bioactive sphingolipids on the growth inhibitory effects of imatinib and exploit sphingolipid metabolism by majorly inhibiting glucosylceramide synthase (GCS) to further sensitize cells to imatinib and/or overcome resistance to imatinib in Ph+ ALL. Methods: Imatinib resistant cell line SD-1R is generated by clonal selection from parental SD-1 cell line by exposing the cells to gradually increased concentration of imatinib. Intracellular lipid levels were measured by HPLC/MS/MS. Cell viability is detected by MTT and trypan blue exclusion assay. Gene and protein expression levels were detected by real time PCR and western blotting, respectively. Results: We detected that intracellular levels of sphingolipids: ceramide, sphingosine and sphingomyelin is increased in response to imatinib in parental SD-1 cells but not in newly generated SD-1R cells. The data showed that these changes are not detectable in SD-1 cells when imatinib is applied in presence of myriocin which is a palmitoyltransferase inhibitor that blocks the first step of de novo synthesis pathway in sphingolipids suggesting that imatinib induced changes in sphingolipids are due to induction of de novo synthesis pathway and a defect in this pathway is contributing the regulation of imatinib resistance in SD-1R cells. Interestingly, another sphingolipid hexosylceramide which is a product of further metabolization of ceramide by the enzyme GCS, levels were elevated in both SD-1 and SD-1R cells. Knowing that, an FDA approved drug eliglustat, which is a GCS inhibitor used in Gaucher's disease is used to block the conversion of ceramide to hexosylceramide to accumulate apoptotic ceramide levels to sensitize cells to imatinib. Indeed, at the lipid levels, this combination resulted in a greater increase in ceramide and sphingosine levels. The reflection of these changes on cell growth was also detected and in parental SD-1 cells, eliglustat application with imatinib is sensitized the cells to imatinib induced growth inhibition by 50% whereas eliglustat and imatinib cotreatment was able to overcome imatinib resistance in SD-1R cells and inhibiting cell growth by 60–70% at 48 h. Summary/Conclusion: Taken together for the first time in the literature, we showed that pharmacological inhibition of GCS by eliglustat and imatinib cotreatment has synergistic cytostatic effects on imatinib resistant Ph+ ALL cells. Additionally, inducing the accumulation of ceramide (and/or sphingosine) by this cotreatment might be used as an approach to sensitize intrinsically / acquired resistant Ph+ ALL." @default.
• W2952754917 created "2019-06-27" @default.
• W2952754917 creator A5000893813 @default.
• W2952754917 creator A5003869748 @default.
• W2952754917 creator A5007779887 @default.
• W2952754917 creator A5010024121 @default.
• W2952754917 creator A5013482646 @default.
• W2952754917 creator A5014370854 @default.
• W2952754917 creator A5019004022 @default.
• W2952754917 creator A5025719686 @default.
• W2952754917 creator A5025807854 @default.
• W2952754917 creator A5040242292 @default.
• W2952754917 creator A5044624520 @default.
• W2952754917 creator A5045493403 @default.
• W2952754917 creator A5049594325 @default.
• W2952754917 creator A5063427645 @default.
• W2952754917 creator A5069688230 @default.
• W2952754917 creator A5070404868 @default.
• W2952754917 creator A5070725992 @default.
• W2952754917 creator A5074418069 @default.
• W2952754917 creator A5074502321 @default.
• W2952754917 creator A5077197819 @default.
• W2952754917 creator A5088505960 @default.
• W2952754917 creator A5089119498 @default.
• W2952754917 creator A5090011921 @default.
• W2952754917 date "2019-06-01" @default.
• W2952754917 modified "2023-10-16" @default.
• W2952754917 title "PS931 ADULT TRIPLE NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA FUSION DETECTION: CHALLENGING AIM FOR PH- ALTERNATIVE THERAPIES" @default.
• W2952754917 doi "https://doi.org/10.1097/01.hs9.0000562000.01287.52" @default.
• W2952754917 hasPublicationYear "2019" @default.
• W2952754917 type Work @default.
• W2952754917 sameAs 2952754917 @default.
• W2952754917 citedByCount "0" @default.
• W2952754917 crossrefType "journal-article" @default.
• W2952754917 hasAuthorship W2952754917A5000893813 @default.
• W2952754917 hasAuthorship W2952754917A5003869748 @default.
• W2952754917 hasAuthorship W2952754917A5007779887 @default.
• W2952754917 hasAuthorship W2952754917A5010024121 @default.
• W2952754917 hasAuthorship W2952754917A5013482646 @default.
• W2952754917 hasAuthorship W2952754917A5014370854 @default.
• W2952754917 hasAuthorship W2952754917A5019004022 @default.
• W2952754917 hasAuthorship W2952754917A5025719686 @default.
• W2952754917 hasAuthorship W2952754917A5025807854 @default.
• W2952754917 hasAuthorship W2952754917A5040242292 @default.
• W2952754917 hasAuthorship W2952754917A5044624520 @default.
• W2952754917 hasAuthorship W2952754917A5045493403 @default.
• W2952754917 hasAuthorship W2952754917A5049594325 @default.
• W2952754917 hasAuthorship W2952754917A5063427645 @default.
• W2952754917 hasAuthorship W2952754917A5069688230 @default.
• W2952754917 hasAuthorship W2952754917A5070404868 @default.
• W2952754917 hasAuthorship W2952754917A5070725992 @default.
• W2952754917 hasAuthorship W2952754917A5074418069 @default.
• W2952754917 hasAuthorship W2952754917A5074502321 @default.
• W2952754917 hasAuthorship W2952754917A5077197819 @default.
• W2952754917 hasAuthorship W2952754917A5088505960 @default.
• W2952754917 hasAuthorship W2952754917A5089119498 @default.
• W2952754917 hasAuthorship W2952754917A5090011921 @default.
• W2952754917 hasBestOaLocation W29527549171 @default.
• W2952754917 hasConcept C121608353 @default.
• W2952754917 hasConcept C190283241 @default.
• W2952754917 hasConcept C2777583451 @default.
• W2952754917 hasConcept C2777851122 @default.
• W2952754917 hasConcept C2778729363 @default.
• W2952754917 hasConcept C2778820342 @default.
• W2952754917 hasConcept C42362537 @default.
• W2952754917 hasConcept C502942594 @default.
• W2952754917 hasConcept C53227056 @default.
• W2952754917 hasConcept C54355233 @default.
• W2952754917 hasConcept C55493867 @default.
• W2952754917 hasConcept C61705674 @default.
• W2952754917 hasConcept C62112901 @default.
• W2952754917 hasConcept C62478195 @default.
• W2952754917 hasConcept C86803240 @default.
• W2952754917 hasConcept C95444343 @default.
• W2952754917 hasConcept C98274493 @default.
• W2952754917 hasConceptScore W2952754917C121608353 @default.
• W2952754917 hasConceptScore W2952754917C190283241 @default.
• W2952754917 hasConceptScore W2952754917C2777583451 @default.
• W2952754917 hasConceptScore W2952754917C2777851122 @default.
• W2952754917 hasConceptScore W2952754917C2778729363 @default.
• W2952754917 hasConceptScore W2952754917C2778820342 @default.
• W2952754917 hasConceptScore W2952754917C42362537 @default.
• W2952754917 hasConceptScore W2952754917C502942594 @default.
• W2952754917 hasConceptScore W2952754917C53227056 @default.
• W2952754917 hasConceptScore W2952754917C54355233 @default.
• W2952754917 hasConceptScore W2952754917C55493867 @default.
• W2952754917 hasConceptScore W2952754917C61705674 @default.
• W2952754917 hasConceptScore W2952754917C62112901 @default.
• W2952754917 hasConceptScore W2952754917C62478195 @default.
• W2952754917 hasConceptScore W2952754917C86803240 @default.
• W2952754917 hasConceptScore W2952754917C95444343 @default.
• W2952754917 hasConceptScore W2952754917C98274493 @default.
• W2952754917 hasIssue "S1" @default.
• W2952754917 hasLocation W29527549171 @default.
• W2952754917 hasLocation W29527549172 @default.
• W2952754917 hasOpenAccess W2952754917 @default.
• W2952754917 hasPrimaryLocation W29527549171 @default.
• W2952754917 hasRelatedWork W1968814687 @default.

• next